Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions revolve around groundbreaking developments such as SeaStar Medical’s device, which claims to reduce pediatric sepsis mortality and treat AKI effectively, showing curiosity and optimism with phrases like 'revolutionary treatment' and 'remarkable potential.' Additionally, posts referencing new models for early AKI prediction underscore the authors' engagement with advancing clinical tools, reflecting strong interest and moderate recognition of the article's importance.
Most posts acknowledge the importance of long-term considerations and new treatment options related to pediatric AKI, showing general agreement with the article's emphasis on ongoing research and clinical implications.
Discussions reflect high interest, especially in innovative therapies like SeaStar Medical's device and modeling studies, indicating a proactive engagement with advancements in this field.
Several posts delve into specifics such as FDA approvals and the need for better prediction models, demonstrating meaningful participation and knowledge exchange.
The focus on innovative treatments and future research highlights perceived significance, though some discussions remain preliminary or exploratory, indicating moderate impact potential.
Acute kidney injury in critically ill children is not all acute: lessons over the last 5 years https://t.co/2tw2JVsmRa @FrontPediatrics #AKI
SeaStar Medical's QUELIMMUNE device cuts pediatric sepsis mortality by 50%, offering revolutionary treatment for acute kidney injury in critically ill children. Groundbreaking FDA-approved therapy shows remarkable potential in clinical trials. #MedicalInnovation #Healthcare
This episode discusses the epidemiology, diagnosis, and management of acute kidney injury in critically ill children, highlighting KDIGO guidelines, biomarkers, and risk stratification tools.
Dr. Dhar and Dr. McGetrick discuss pediatric AKI, covering its definition, epidemiology, diagnosis using KDIGO guidelines, risk stratification with biomarkers, and clinical management in critical care. An essential…
This session discusses pediatric acute kidney injury, its epidemiology, diagnosis using KDIGO guidelines, and strategies for early detection and management in critically ill children. Dr. Dhar and Dr. McGetrick provide…
SeaStar Medical's QUELIMMUNE device cuts pediatric sepsis mortality by 50%, offering revolutionary treatment for acute kidney injury in critically ill children. Groundbreaking FDA-approved therapy shows remarkable potential in clinical trials. #MedicalInnovation #Healthcare
External Validation, Re-Calibration, and Extension of a Prediction Model of Early Acute Kidney Injury in Critically Ill Children using Multi-Center Data https://www.medrxiv.org/content/10.1101/2025.02.05.25321680v1
Acute kidney injury in critically ill children is not all acute: lessons over the last 5 years https://t.co/2tw2JVsmRa @FrontPediatrics #AKI
AN